Acrivon Therapeutics, Inc. Common Stock
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific propri… Read more
Acrivon Therapeutics, Inc. Common Stock (ACRV) - Total Liabilities
Latest total liabilities as of September 2025: $16.70 Million USD
Based on the latest financial reports, Acrivon Therapeutics, Inc. Common Stock (ACRV) has total liabilities worth $16.70 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Acrivon Therapeutics, Inc. Common Stock - Total Liabilities Trend (2020–2024)
This chart illustrates how Acrivon Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Acrivon Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Acrivon Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
1480
TWO:1480
|
Taiwan | NT$3.27 Billion |
|
Niloerngruppen AB Series B
ST:NIL-B
|
Sweden | Skr231.51 Million |
|
SEC
KQ:081180
|
Korea | ₩60.91 Billion |
|
The Brooker Group Public Company Limited
BK:BTC
|
Thailand | ฿695.83 Million |
|
COPRD
NYSE MKT:COPRD
|
USA | $6.19 Million |
|
Tier1 Technology S.A.
MC:TR1
|
Spain | €6.52 Million |
|
SRV Group plc
HE:SRV1V
|
Finland | €377.80 Million |
|
Xtant Medical Holdings Inc
NYSE MKT:XTNT
|
USA | $55.94 Million |
Liability Composition Analysis (2020–2024)
This chart breaks down Acrivon Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.75 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.11 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Acrivon Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Acrivon Therapeutics, Inc. Common Stock (2020–2024)
The table below shows the annual total liabilities of Acrivon Therapeutics, Inc. Common Stock from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $19.80 Million | +16.00% |
| 2023-12-31 | $17.07 Million | +58.78% |
| 2022-12-31 | $10.75 Million | -91.76% |
| 2021-12-31 | $130.40 Million | +1130.38% |
| 2020-12-31 | $10.60 Million | -- |